Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    AL-LAD molecular structure

    AL-LAD Stats & Data

    Aladdin N-allyl-nor-lsd 6-allyl-6-nor-lsd allad
    NPS DataHub
    MW349.48
    FormulaC22H27N3O
    CAS65527-61-9
    IUPAC(6~{a}~{R},9~{R})-~{N},~{N}-diethyl-7-prop-2-enyl-6,6~{a},8,9-tetrahydro-4~{H}-indolo[4,3-fg]quinoline-9-carboxamide
    SMILESC=CCN1CC(C=C2C1Cc1cnc3cccc2c13)C(=O)N(CC)CC
    InChIKeyJCQLEPDZFXGHHQ-QRIPLOBPSA-N
    2020/5.2 Δ9 10-Ergolene; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic
    Half-Life Unknown in humans; presumed similar order to LSD (approx. 3–5 hours) based on structural/pharmacodynamic similarity.

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (full)
    5-HT1 receptor agonist
    5-HT2C receptor agonist
    Dopamine D1 receptor agonist
    Dopamine D2 receptor agonist

    History & Culture

    AL-LAD was first synthesized and described in the scientific literature in 1976. The compound received further attention in 1984 when researchers Andrew J. Hoffman and David Nichols investigated it as part of a broader series of LSD analogues, which also included ETH-LAD and PRO-LAD. This academic interest culminated in 1997 when Alexander Shulgin documented the substance in his landmark book TiHKAL (Tryptamines I Have Known And Loved), providing a dose range of 80-160 µg and a duration of 6-8 hours. Shulgin characterized AL-LAD as "one of the several very potent compounds in a large series of nor-LSD analogues." Despite this early academic documentation, AL-LAD saw little to no recreational use until 2013, when it emerged on the online research chemical market. The compound quickly gained traction as a grey-market alternative to LSD, commonly marketed alongside other novel lysergamides such as 1P-LSD, ALD-52, and ETH-LAD. By 2015, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported its presence in the European drug market for the first time, marking its transition from an obscure research compound to a recognized designer drug. The substance is sometimes referred to by the street name "Aladdin."

    Subjective Effects

    Physical
    • Spontaneous tactile sensations: The 'body high' of AL-LAD can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast moving, sharp and location specific tingling sensation. For some it is manifested spontaneously at different unpredictable points throughout the trip, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. At moderate to high doses of AL-LAD, this sensation will usually hit its highest level and become so overwhelming that people find themselves writhing on the floor in complete pleasure.
    • Stimulation: In terms of its effects on the physical energy levels of the tripper, AL-LAD is usually considered to be very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing.
    • Nausea: Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly once the tripper has vomited or gradually fades by itself as the peak sets in.
    • Enhancement of touch: Feelings of enhanced tactile sensation are consistently present at moderate levels throughout most AL-LAD trips. Once level 8A geometry is reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once is consistently present.
    • Increased bodily control
    Cognitive

    In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, AL-LAD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

    • Enhancement of current mind state
    • Acceleration of thought
    • Feelings of fascination, importance and awe
    • Time distortion
    • Introspection
    • Déjà vu
    • Multiple thought streams
    • Removal of cultural filter
    • Conceptual thinking
    • Ego suppression, loss and death
    • Thought loops
    • Feelings of interdependent opposites
    • Delusions
    • States of unity and interconnectedness
    Sensory
    Auditory
    • Enhancements
    • Distortions
    • Hallucinations
    Visual · Distortions
    • Visual drifting: (Melting, Breathing, Morphing and Flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in appearance. The distortions are slow and smooth in motion and fleeting in their appearance.
    • Tracers
    • After images
    • Depth Perception Distortions
    • Symmetrical texture repetition
    • Colour shifting
    • Scenery slicing
    Visual · Enhancements
    • Increased visual acuity
    • Enhancement of colour
    • Enhanced pattern recognition
    Visual · Hallucinatory States

    AL-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.

    • Transformations
    • Internal hallucinations: Although AL-LAD is technically capable of producing hallucinatory states in a fashion that is on par with psilocin or DMT in its vividness and intensity, these effects are extremely rare and inconsistent in comparison. Whilst traditional psychedelics such as LSA, Ayahuasca and Mescaline will induce internal hallucinations near consistently at level 5 geometry and above, AL-LAD will for most simply go straight into Level 8A visual geometry. On the rare occasion that they are induced however, they can be comprehensively described as lucid in believability, interactive in style, new experiences in content, autonomous in controllability and geometry-based in appearance.

    Forked from Subjective Effect Documentation by Josie Kins, July 2014. Via dose.wiki (CC0).

    Toxicity

    PsychonautWiki

    The toxicity and long-term health effects of recreational AL-LAD use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AL-LAD is a research chemical with very little history of human usage. The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. As with other psychedelic substances, there are relatively few physical side effects that have been reported associated with acute AL-LAD exposure.

    Overdose

    The LD50 of AL-LAD is unknown. Adverse psychological reactions are common especially at higher dosages. Some of these include anxiety, delusions, panic attacks and more rarely seizures.

    Effect Profile

    Curated + 61 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10104.5
    Headspace Depth×3
    10103.7
    Auditory Effects×1
    10103.2
    Body Load / Somatic Effects×1
    109.95.0
    Catalog Erowid BlueLight

    Community Effects

    TripSit
    Positive
    euphoria visual enhancement music enhancement body high energy warmth
    Negative
    tachycardia

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; presumed similar order to LSD (approx. 3–5 hours) based on structural/pharmacodynamic similarity.
    Addiction Potential
    Low; not considered habit-forming or addictive. Tolerance develops rapidly with repeated use, similar to LSD.

    Tolerance Decay

    Full tolerance 3d Half tolerance 7d Baseline ~14d

    Rapid tolerance accrues after a single experience, similar to LSD. Cross-tolerance across serotonergic lysergamides is partial; spacing experiences by 2+ weeks reduces tolerance-related dose escalation. Data are inferred from LSD literature plus user reports for AL-LAD.

    Cross-Tolerances

    LSD
    Other lysergamides (e.g., ALD-52, 1P-LSD)

    Experience Report Analysis

    Erowid BlueLight
    75 Reports
    36 Single-substance
    2012–2022 Date Range
    66 With Age Data
    29 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 61 experience reports (36 single-substance Erowid + 25 Bluelight)

    61 Reports
    122 Effects Detected
    63 Positive
    34 Adverse
    25 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Positive Effects 63

    Color Enhancement 63.9% (95% interval 51 to 75 percent) 85%
    Visual Distortions 59.0% (95% interval 46 to 70 percent) 88%
    Euphoria 55.8% (95% interval 43 to 68 percent) 89%
    Music Enhancement 44.3% (95% interval 32 to 57 percent) 87%
    Open-Eye Visuals 42.6% (95% interval 31 to 55 percent) 90%
    Stimulation 37.7% (95% interval 27 to 50 percent) 84%
    Closed-Eye Visuals 37.7% (95% interval 27 to 50 percent) 86%
    Visual Trails 36.0% (95% interval 20 to 56 percent) 84%
    Joy 36.0% (95% interval 20 to 56 percent) 88%
    Empathy 32.8% (95% interval 22 to 45 percent) 90%
    Morphing 32.0% (95% interval 17 to 52 percent) 84%
    Awe 32.0% (95% interval 17 to 52 percent) 83%
    Introspection 31.2% (95% interval 21 to 44 percent) 82%
    Melting/flowing 28.0% (95% interval 14 to 48 percent) 86%
    Entity Imagery 28.0% (95% interval 14 to 48 percent) 81%
    Thought Acceleration 28.0% (95% interval 14 to 48 percent) 76%
    Surface Breathing 28.0% (95% interval 14 to 48 percent) 84%
    Body High 26.2% (95% interval 17 to 38 percent) 86%
    Contentment 24.0% (95% interval 12 to 43 percent) 82%
    Fractal Imagery 20.0% (95% interval 9 to 39 percent) 87%

    Adverse Effects 34

    Anxiety 45.9% (95% interval 34 to 58 percent) 83%
    Memory Suppression 27.8% (95% interval 16 to 44 percent) 70%
    Confusion 26.2% (95% interval 17 to 38 percent) 80%
    Nausea 24.6% (95% interval 16 to 37 percent) 71%
    Sadness 24.0% (95% interval 12 to 43 percent) 78%
    Muscle Tension 21.3% (95% interval 13 to 33 percent) 85%
    Sweating 16.7% (95% interval 8 to 32 percent) 70%
    Thought Loops 16.4% (95% interval 9 to 28 percent) 75%
    Fear 16.0% (95% interval 6 to 35 percent) 86%
    Depersonalization 12.0% (95% interval 4 to 30 percent) 78%
    Thought Disorganization 12.0% (95% interval 4 to 30 percent) 78%
    ⚠ Psychosis 11.1% (95% interval 4 to 25 percent) 70%
    Headache 9.8% (95% interval 5 to 20 percent) 82%
    Increased Heart Rate 8.3% (95% interval 3 to 22 percent) 70%
    Loss Of Motor Control 8.0% (95% interval 2 to 25 percent) 80%
    Crying 8.0% (95% interval 2 to 25 percent) 85%
    Insomnia 8.0% (95% interval 2 to 25 percent) 78%
    Ataxia 4.0% (95% interval 1 to 20 percent) 80%
    Itching 4.0% (95% interval 1 to 20 percent) 75%
    Tremor 4.0% (95% interval 1 to 20 percent) 80%
    Show 14 more adverse effects
    Chills 4.0% (95% interval 1 to 20 percent) 75%
    Depth Distortion 4.0% (95% interval 1 to 20 percent) 85%
    Panic 4.0% (95% interval 1 to 20 percent) 85%
    Social Anxiety 4.0% (95% interval 1 to 20 percent) 85%
    Dry Mouth 4.0% (95% interval 1 to 20 percent) 75%
    Delusion 4.0% (95% interval 1 to 20 percent) 65%
    Loneliness 4.0% (95% interval 1 to 20 percent) 70%
    Jaw Clenching 4.0% (95% interval 1 to 20 percent) 85%
    Tension 4.0% (95% interval 1 to 20 percent) 90%
    Bloating 4.0% (95% interval 1 to 20 percent) 80%
    Stomach Cramps 4.0% (95% interval 1 to 20 percent) 85%
    Irritability 4.0% (95% interval 1 to 20 percent) 75%
    Disrupted Sleep Architecture 4.0% (95% interval 1 to 20 percent) 75%
    Orgasm Suppression 4.0% (95% interval 1 to 20 percent) 75%

    Dose-Response Correlation

    How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

    Not drawn, too few reports (a dose tier needs 20): Oral Heavy (n=13). Why 20?

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

    Oral

    Median: 150.0 µg IQR: 150.0–300.0 µg n=22 2 outliers left out

    Sublingual

    Median: 150.0 µg IQR: 93.8–450.0 µg n=11 1 outlier left out

    Real-World Dose Distribution

    62K Doses

    From 73 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

    Oral (n=36)

    Median: 0.15mg 25th: 0.15mg 75th: 0.3mg 90th: 0.33mg

    Sublingual (n=21)

    Median: 0.15mg 25th: 0.07mg 75th: 0.3mg 90th: 0.45mg

    Common Combinations

    Most co-occurring substances, as a share of all 75 reports filed under AL-LAD; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 57 reports that give one; whiskers are 95% intervals

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

    Oral

    Median: 0.003 mg/kg IQR: 0.002–0.005 mg/kg n=20 2 outliers left out

    Unknown

    Median: 0.004 mg/kg IQR: 0.002–0.004 mg/kg n=10

    Sublingual

    Median: 0.003 mg/kg IQR: 0.001–0.005 mg/kg n=11

    Redose Patterns

    Redosing behavior across 60 reports

    16.7% (95% interval 9 to 28 percent) Redosed
    1.2 Avg Doses
    120m Median Interval

    Legal Status

    Not scheduled under the United Nations Convention on Psychotropic Substances
    Country Status Notes
    Austria Unscheduled (potentially controlled as analogue) Not specifically scheduled, but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD.
    Denmark Illegal Specifically named on the list of controlled substances as of August 25, 2015.
    Finland Banned Listed in a government decree banning psychoactive substances from the consumer market.
    France Illegal Prohibited under national drug control legislation.
    Germany NpSG controlled Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import for market distribution, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty.
    Japan Controlled substance Designated as a controlled substance effective February 28, 2020.
    Latvia Controlled (as analogue) Although not officially scheduled by name, controlled as an LSD structural analogue under an amendment enacted June 1, 2015.
    Sweden Schedule I (Narcotic) Added to the Narcotic Drugs Punishments Act under Schedule I (substances without accepted medical use) on January 26, 2016. Listed in Medical Products Agency regulation HSLF-FS 2015:35 under multiple names including 6-allyl-6-nor-LSD.
    Switzerland Illegal (Verzeichnis E) Specifically named as a controlled substance under Verzeichnis E, effective December 1, 2015, as part of a broader scheduling of 21 novel psychoactive substances.
    Turkey Illegal Prohibited under national drug control legislation as of February 2016.
    United Kingdom Class A Specifically named in the Misuse of Drugs Act 1971 as a Class A controlled substance. The UK Advisory Council on the Misuse of Drugs recommended scheduling on June 10, 2014, notably without identifying any harm associated with its use. The ban was enacted January 6, 2015 via The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
    United States Unscheduled (Analogue Act applies) Not specifically scheduled at the federal level. However, as a structural analogue of the Schedule I substance LSD, it may be prosecuted under the Federal Analogue Act when sold, possessed, or consumed for human consumption. Research and analytical use are not subject to prosecution under this framework.

    Harm Reduction

    drugs.wiki

    AL-LAD is a lysergamide closely related to LSD, first synthesized in the 1970s and popularized as a research chemical in the 2010s. It is reported to produce a psychedelic experience similar to LSD but often described as more visually oriented, with a lighter, more euphoric, and less anxious character. It is usually sold on blotter paper and is active at microgram doses. There is little evidence of physical toxicity or long-term organ harm, but psychological risks (such as anxiety, panic, or precipitating mania/psychosis in vulnerable individuals) are possible, especially at high doses or in unsuitable settings. For drug checking, indole-positive reagents (Ehrlich) typically turn purple with lysergamides, and fresh LSD-family blotters fluoresce under UV; however, adulteration (e.g., adding tryptamine to mimic Ehrlich purple) can confound results—use multiple tests or a lab where possible. Avoid redosing for at least 3 hours; blotters vary in potency and occasionally contain unexpected substances with delayed onset. Store blotters cool, dark, and dry; UV light and heat accelerate degradation. Microgram potency makes precise measurement difficult—if handling liquid or powder, use volumetric dosing and label solutions clearly. AL-LAD is illegal in some jurisdictions.

    References

    ← Back to AL-LAD